Over the past five years a significant number of new drugs have been introduced to treat breast cancer. Many patients, even with metastatic breast cancer, can remain on the same treatment for years.
This webinar will update GPs about new breast cancer drugs: how these work, the main side effects, and the signs and symptoms of these effects that you (and your patient) need to look out for.
This webinar is specifically for primary care clinicians, including nurses. It will feature a presentation followed by a Q&A with a panel of experts.
The Research & Education Lead, Breast Cancer role is held jointly with Professor Bruce Mann to facilitate surgical collaboration with research and clinical trials in the breast cancer tumour stream.
Belinda holds a joint appointment with Austin Health as a Medical Oncologist, and the Olivia Newton-John Cancer Research Institute (ONJCRI) as a Clinician Scientist with a specific interest in breast cancer.
She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s degree at the University of London and the Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays in hormone receptor positive breast cancer.
She continues her translational research at the ONJCRI, investigating improving personalisation and minimising toxicities for patients with breast cancer.
Through the Translational Breast Cancer Program at ONJCRI, she has established a Breast Cancer Biobank focusing on the collection of real-time primary and metastatic tumour specimens for translational analysis.
Dr Yeo is the principal investigator on multiple breast cancer clinical trials, including an investigator-initiated pilot study to evaluate the decision impact for a non-molecular marker for hormone receptor positive breast cancer to improve clinical and patient decision-making.
Dr Yeo is a member of the VCCC Alliance Cancer Education and Training Advisory Committee, supervisor and mentor of medical oncology trainees, honours and PhD students and has contributed to the Master of Cancer Sciences. She is also a member of the Precision Oncology Steering Group and Chair of the Breast Cancer Group for Clinical Trials Australia.
Full program coming soon.
